Anteris Technologies (ASX:AVR) - Cotización, noticias y análisis

Resumen de acción AVR

Anteris Technologies Ltd, empresa dedicada al corazón estructural, diseña, desarrolla y comercializa dispositivos médicos.

Acerca de la empresa

AVR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 10.26%

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 11.2% al año durante los próximos 3 años

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

No tiene ingresos significativos (A$4M)

Competidores de Anteris Technologies Ltd

EBR Systems

ASX:EBR

AU$298.8m

ImpediMed

ASX:IPD

AU$163.9m

Cyclopharm

ASX:CYC

AU$162.9m

Optiscan Imaging

ASX:OIL

AU$70.2m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Anteris Technologies
Historical stock prices
Current Share Price	AU$21.00
52 Week High	AU$24.38
52 Week Low	AU$15.58
Beta	0.75
1 Month Change	-9.40%
3 Month Change	19.32%
1 Year Change	-8.70%
3 Year Change	137.29%
5 Year Change	250.00%
Change since IPO	-72.37%

Noticias y actualizaciones recientes

Recent updates

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Jul 08

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

May 07

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Feb 21

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

Dec 10

Rentabilidad de los accionistas

	AVR	AU Medical Equipment	Mercado AU
7D	-4.1%	-0.7%	0.5%
1Y	-8.7%	16.8%	6.2%

Rentabilidad vs. Industria: AVR obtuvo unos resultados inferiores a los del sector Australian Medical Equipment , que el año pasado arrojó un rendimiento del 14.7%.

Rentabilidad vs. Mercado: AVR obtuvo unos resultados inferiores a los del mercado Australian, que fue del 5.6% el año pasado.

Volatilidad de los precios

Is AVR's price volatile compared to industry and market?
AVR volatility
AVR Average Weekly Movement	4.4%
Medical Equipment Industry Average Movement	10.1%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.5%

Precio estable de las acciones: AVR no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de AVR (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1999	n/a	Wayne Paterson	www.anteristech.com

Anteris Technologies Ltd, una empresa de cardiología estructural, diseña, desarrolla y comercializa dispositivos médicos. La empresa fabrica y vende ADAPT, un producto de tejido regenerativo. Su principal producto es la DurAVRTM, una válvula cardíaca transcatéter para el tratamiento de la estenosis aórtica.

Resumen de fundamentos de Anteris Technologies Ltd

¿Cómo se comparan los beneficios e ingresos de Anteris Technologies con su capitalización de mercado?
Estadísticas fundamentales de AVR
Capitalización bursátil	AU$413.02m
Beneficios(TTM)	-AU$67.33m
Ingresos (TTM)	AU$4.11m

98.1x

Ratio precio-ventas (PS)

-6.0x

Ratio precio-beneficio (PE)

¿Está AVR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de AVR
Ingresos	AU$4.11m
Coste de los ingresos	AU$1.59m
Beneficio bruto	AU$2.52m
Otros gastos	AU$69.85m
Beneficios	-AU$67.33m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-3.51
Margen bruto	61.23%
Margen de beneficio neto	-1,637.85%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado AVR a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción AVR

Recompensas

Análisis de riesgos

Competidores de Anteris Technologies Ltd

ASX:EBR

AU$298.8m

ASX:IPD

AU$163.9m

ASX:CYC

AU$162.9m

ASX:OIL

AU$70.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Anteris Technologies Ltd, Annual General Meeting, May 29, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 40 million.

First half 2023 earnings released: AU$2.01 loss per share (vs AU$1.73 loss in 1H 2022)

Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

Anteris Technologies Announces First Successful Implantation of Duravr™ Thv in A Valve-In-Valve Procedure

Recent updates

Anteris Technologies Ltd, Annual General Meeting, May 29, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 40 million.

First half 2023 earnings released: AU$2.01 loss per share (vs AU$1.73 loss in 1H 2022)

Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

Anteris Technologies Announces First Successful Implantation of Duravr™ Thv in A Valve-In-Valve Procedure

Full year 2022 earnings released: AU$3.32 loss per share (vs AU$3.09 loss in FY 2021)

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 35.000016 million.

Anteris Technologies Ltd announced that it expects to receive AUD 50 million in funding from Yorkville Advisors Global LP

Anteris Technologies Ltd Announces 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve Aortic Stenosis First in Human Study

Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI (cMRI) in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human)

Anteris Technologies Ltd Announces Results Demonstrating Restoration of Normal Pre-Disease Flow

Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston

First half 2022 earnings released: EPS: AU$0 (vs AU$1.58 loss in 1H 2021)

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Anteris Technologies Ltd Provides Update on First In Human DurAVR THV Study

Anteris Announces 6 Month Follow Up of First Cohort of 5 Patients

Anteris Technologies Ltd Announces Successful Completion of Second First-In-Human Study

Anteris Technologies Ltd Announces Expansion of First in Human Trial

Anteris Technologies Ltd Appoints Dion Stub to Medical Advisory Board

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 27.6 million.

Anteris Technologies Ltd announced that it has received AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd announced that it expects to receive AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd, Annual General Meeting, May 19, 2022

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) cancelled the acquisition of Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial

Anteris Technologies Ltd Reports New Patent Application for ADAPT

Independent Chairman of the Board exercised options to buy AU$58k worth of stock.

First half 2021 earnings released: AU$1.58 loss per share (vs AU$1.01 loss in 1H 2020)

Anteris Technologies Ltd announced that it has received AUD 9 million in funding

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies Ltd Announces Successful Completion of Proof of Concept (Poc) Animal Study

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.327895 million.

Anteris Technologies Ltd announced that it expects to receive AUD 2.327895 million in funding

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

New 90-day high: AU$5.52

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Full year 2020 earnings released

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.171499 million.

New 90-day high: AU$4.30

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.068135 million.

Anteris Technologies Announces Resignation of Yanheng Wu as A Non-Executive Director on the Board

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

New 90-day low: AU$3.50

Anteris Technologies Ltd Reports Interim Results from Anti-Calcification Study

Anteris Technologies Limited Announces DurAVR Valve Patient Outcomes

First half earnings released

New 90-day low - AU$4.30

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Anteris Technologies Ltd

98.1x

-6.0x